Huifen Wang

机构：GlaxoSmithKline (United States), Huazhong University of Science and Technology · ORCID：0000-0001-9699-342X

发表论文 201 篇 · 总被引 3470 次 · h-index 32

代表论文

• Long-term follow-up after authorization of gene therapy: leveraging real-world data (2025 · Drug Discovery Today · 被引 27)
• Unveiling microbial dynamics in lung adenocarcinoma and adjacent nontumor tissues: insights from nicotine exposure and diverse clinical stages via nanopore sequencing technology (2024 · Frontiers in Cellular and Infection Microbiology · 被引 17)
• Theaflavins attenuate iron overload-induced liver oxidative injury by inhibiting hepatocyte ferroptosis (2025 · International Journal of Biological Sciences · 被引 15)
• Skeletal Muscle Index–Based Cachexia Index as a Predictor of Prognosis in Patients With Cancer: A Meta-Analysis and Systematic Review (2024 · Nutrition Reviews · 被引 12)
• Efficacy of Donor-Recipient-Matched Faecal Microbiota Transplantation in Patients with IBS-D: A Single-Centre, Randomized, Double-Blind Placebo-Controlled Study (2024 · Digestion · 被引 11)
• Preparation of rapeseed protein by enzymatic hydrolysis assisted alkaline water extraction and its nutritional value in comparison with rapeseed meal and soybean protein concentrate (2025 · LWT · 被引 8)